L-Carnitine-conjugated nanoparticles to promote permeation across blood–brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2
Source abstract
Abstract
Overcoming blood–brain barrier (BBB) and targeting tumor cells are two key steps for glioma chemotherapy. By taking advantage of the specific expression of Na+-coupled carnitine transporter 2 (OCTN2) on both brain capillary endothelial cells and glioma cells, l-carnitine conjugated poly(lactic-co-glycolic acid) nanoparticles (LC-PLGA NPs) were prepared to enable enhanced BBB permeation and glioma-cell targeting. Conjugation of l-carnitine significantly enhanced the uptake of PLGA nanoparticles in the BBB endothelial cell line hCMEC/D3 and the glioma cell line T98G. The uptake was dependent on Na+ and inhibited by the excessive free l-carnitine, suggesting involvement of OCTN2 in the process. In vivo mouse studies showed that LC-PLGA NPs resulted in high accumulation in the brain as indicated by the biodistribution and imaging assays. Furthermore, compared to Taxol and paclitaxel-loaded unmodified PLGA NPs, the drug-loaded LC-PLGA NPs showed improved anti-glioma efficacy in both 2D-cell and 3D-spheroid models. The PEG spacer length of the ligand attached to the nanoparticles was optimized, and the formulation with PEG1000 (LC-1000-PLGA NPs) showed the maximum targeting efficiency. We conclude that l-carnitine-mediated cellular recognition and internalization via OCTN2 significantly facilitate the transcytosis of nanoparticles across BBB and the uptake of nanoparticles in glioma cells, resulting in improved anti-glioma efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Metabolism and Genetic Disorders · Drug Transport and Resistance Mechanisms · Pharmacological Effects and Toxicity Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Municipal Key Laboratory of Biopharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China;
Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA;
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
Funding
National Nature Science Foundation of China · National Basic Research Program of China · Texas Tech University Health Sciences Center · China Scholarship Council
References (41)
Show source-provided references
1. Ostrom QT · Neuro Oncol · 2012 · 14 · 1–56
2. Ostrom QT · Neuro Oncol · 2016 · 1 · i110.1093/neuonc/nov297 ↗
3. 10.1016/j.pharmthera.2010.04.01510.1016/j.pharmthera.2010.04.015 ↗
4. 10.1017/S146239941100188810.1017/S1462399411001888 ↗
5. 10.1016/j.ijpharm.2012.06.02510.1016/j.ijpharm.2012.06.025 ↗
6. 10.1124/mi.3.2.9010.1124/mi.3.2.90 ↗
7. 10.2174/13892011280334179810.2174/138920112803341798 ↗
8. 10.1517/17425247.2012.68272610.1517/17425247.2012.682726 ↗
9. 10.1016/j.ajps.2017.05.00610.1016/j.ajps.2017.05.006 ↗
10. 10.1016/j.ajps.2016.12.00110.1016/j.ajps.2016.12.001 ↗
11. 10.4155/tde.10.7610.4155/tde.10.76 ↗
12. 10.4155/tde.15.3210.4155/tde.15.32 ↗
13. 10.1517/14728222.2015.104236410.1517/14728222.2015.1042364 ↗
14. 10.1021/nn406285x10.1021/nn406285x ↗
15. 10.1016/j.biomaterials.2013.09.09410.1016/j.biomaterials.2013.09.094 ↗
16. 10.1016/j.biomaterials.2013.08.03010.1016/j.biomaterials.2013.08.030 ↗
17. 10.1021/bc900369d10.1021/bc900369d ↗
18. 10.1016/j.colsurfb.2016.01.04110.1016/j.colsurfb.2016.01.041 ↗
19. 10.1006/bbrc.1998.866910.1006/bbrc.1998.8669 ↗
20. 10.1074/jbc.273.32.2037810.1074/jbc.273.32.20378 ↗
21. 10.1046/j.1471-4159.2001.00621.x10.1046/j.1471-4159.2001.00621.x ↗
22. Miecz D · J Neurochem · 2008 · 104 · 11310.1111/j.1471-4159.2007.05024.x ↗
23. 10.1111/j.1471-4159.2004.02752.x10.1111/j.1471-4159.2004.02752.x ↗
24. 10.1002/bdd.37110.1002/bdd.371 ↗
25. 10.1016/j.mam.2004.06.00310.1016/j.mam.2004.06.003 ↗
26. 10.1039/C7RA02102J10.1039/C7RA02102J ↗
27. 10.1002/cbic.20160009210.1002/cbic.201600092 ↗
28. 10.1016/j.colsurfb.2015.03.03610.1016/j.colsurfb.2015.03.036 ↗
29. 10.1002/bdd.181610.1002/bdd.1816 ↗
30. 10.1002/adhm.20170016510.1002/adhm.201700165 ↗
31. 10.1016/j.jconrel.2006.10.01510.1016/j.jconrel.2006.10.015 ↗
32. 10.1158/0008-5472.CAN-10-102210.1158/0008-5472.CAN-10-1022 ↗
33. 10.1016/j.biomaterials.2010.09.00210.1016/j.biomaterials.2010.09.002 ↗
34. 10.1016/j.biomaterials.2011.07.00410.1016/j.biomaterials.2011.07.004 ↗
35. 10.1016/j.ajps.2014.04.00410.1016/j.ajps.2014.04.004 ↗
36. 10.3390/molecules1409326810.3390/molecules14093268 ↗
37. 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
38. 10.1080/10717544.2017.137731610.1080/10717544.2017.1377316 ↗
39. 10.1016/S0006-3495(00)76434-410.1016/S0006-3495(00)76434-4 ↗
40. 10.1016/j.trac.2016.11.00910.1016/j.trac.2016.11.009 ↗
41. 10.1016/j.drudis.2012.10.00310.1016/j.drudis.2012.10.003 ↗